PREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS AND EVALUATION OF HCV-CORE ANTIGEN TEST IN SCREENING PATIENTS FOR DIALYSIS IN SANA'A CITY, YEMEN

  • Samira H Hanash Medical Microbiology, Faculty of Medicine and Health Sciences, Taiz University, Republic of Yemen.
  • Hassan A. Al-Shamahy Medical Microbiology and Clinical Immunology, Faculty of Medicine and Health Sciences, Sana’a University, Republic of Yemen.
  • Mohammed Hussein Saleh Bamshmous Medical Microbiology and Clinical Immunology, Faculty of Medicine and Health Sciences, Sana’a University, Republic of Yemen.
10.22270/ujpr.v4i2.251

Keywords:

Genotype, Haemodialysis, Hepatitis C virus, HCV core antigen, HCV antibodies, PCR HCV-RNA, Yemen

Abstract

Objective: Hepatitis C virus infection is a constant worldwide public health concern. The prevalence of HCV infection is higher in patients on chronic haemodialysis (HD) than in the general population. Despite the control of blood products, hepatitis C virus transmission is still being observed among patients undergoing dialysis. Detection systems for serum HCV antibodies are insensitive in the acute phase because of the long serological window. Direct detection of HCV depends on PCR test but this test is not suitable for routine screening.  The objective of this study was to determine prevalence of HCV, genotyping and  if  HCV core antigen test could be a better alternative to NAT techniques for the diagnosis of HCV infection during the window period and whether the sensitivity for antibody detection is preserved.

Methods: Current study includes screening of 159 patients on long-term dialysis by HVC antibodies test, PCR HCV-RNA and HCV core antigen test by commercial tests.

Results: The prevalence of HCV was 10.7% (17 patients) and genotype 4 was the most common one (64.7%). The sensitivity of HCV core antigen test was 94.1%, the specificity 100%, the positive predictive power 100%, and the negative predictive power 97.9%. In conclusions; patients on maintenance HD in Yemen have a high prevalence of HCV infection comparing with general population; and genotype 4 is predominant.

Conclusion: The performance of serological detection of HCV core antigen was better than that of HCV antibodies test and   may be an alternative to nucleic acid amplification technology (NAT) for routine monitoring of patients on chronic dialysis.

                       r32.gif

Peer Review History:

Received 6 February 2019;   Revised 12 March; Accepted 30 April; Available online 15 May 2019

Academic Editor: Dr. Jennifer Audu-Peterorcid22.jpg, University of Jos, Nigeria, drambia44@gmail.com

Received file:blue_23983.gif                Reviewer's Comments:download_logo_r_29189.gif

Average Peer review marks at initial stage: 5.5/10

Average Peer review marks at publication stage: 8.5/10

Reviewer(s) detail:

Dr. O.J Owolabiorcid22.jpg, University of Benin, Nigeria, owolabi@uniben.edu

Dr. Dalia Kamal Zaffar Aliorcid22.jpg, Modern University for technology and information, Egypt, dr.moda88@gmail.com

Downloads

Download data is not yet available.
Crossmark
Statistics
466 Views | 236 Downloads
Dimension Citations

Published

2019-05-05

How to Cite

Hanash, S. H., H. A. Al-Shamahy, and M. H. S. Bamshmous. “PREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS AND EVALUATION OF HCV-CORE ANTIGEN TEST IN SCREENING PATIENTS FOR DIALYSIS IN SANA’A CITY, YEMEN”. Universal Journal of Pharmaceutical Research, vol. 4, no. 2, May 2019, doi:10.22270/ujpr.v4i2.251.

Issue

Section

Research Articles
Share |

Most read articles by the same author(s)

1 2 3 4 > >>